Experience

Araris Biotech’s up to $1.14 Billion Acquisition by Taiho Pharmaceutical

March 17, 2025

Cooley advised Araris Biotech, a Swiss biotechnology company developing next-generation antibody-drug conjugates, on its definitive agreement to be acquired by Japan-based Taiho Pharmaceutical for up to $1.14 billion in cash.

Read more

Related contacts

Bill Roegge
Partner, New York
Kenneth Krisko
Partner, Reston
Simon Amies
Partner, London
Rita Sobral
Special Counsel, London
Stephanie Parker Palmer
Special Counsel, Reston
Michael Bergmann
Partner, Washington, DC
Brandon W. Fenn
Partner, New York
Eileen Marshall
Partner, Washington, DC
Jeremy Morrison
Partner, Washington, DC
Stella Sarma
Partner, Brussels
Ryan Vann
Partner, Chicago
Natasha Leskovsek
Of Counsel, Washington, DC
Matthew Choy
Associate, New York
Kyle Hess
Associate, New York
Katie Kaufman
Associate, Boston
Edward (Teddy) Nimetz
Associate, New York
Alexandra Paterson
Associate, London
Joseph Perry
Associate, Reston
María Álvarez Requejo Heredero
Associate, Brussels

Related Practices & Industries

Enavate Sciences Co-Leads Normunity’s $75 Million Series B

January 13, 2025

Cooley advised Enavate Sciences, a top investment firm, as the co-lead investor in the $75 million Series B financing round of Normunity, a biotechnology company creating novel anticancer therapies. Lawyers Marc Recht, Brandon Fenn and Barry Kuang led the Cooley team advising Enavate Sciences.

Related contacts

Marc Recht
Partner, Boston
Brandon W. Fenn
Partner, New York
Barry Kuang
Associate, Boston
Liz Gold
Associate, New York
Stephanie Gentile
Partner, New York

Related Practices & Industries

Windward Bio Closes $200 Million Series A

January 10, 2025

Cooley advised Windward Bio, a clinical-stage drug development company committed to improving outcomes for people living with advanced immunological diseases, on its $200 million Series A financing round. Partners Brandon Fenn and Ryan Sansom led the Cooley team advising Windward Bio.

Related contacts

Brandon W. Fenn
Partner, New York
Ryan Sansom
Partner, Boston
Alex Abelson
Associate, New York

Related Practices & Industries

Enavate Sciences Invests in Aviceda Therapeutics $207.5 Million Series C

January 7, 2025

Cooley advised Enavate Sciences, a top investment firm, on its participation in the $207.5 million Series C financing round of Aviceda Therapeutics, a clinical-stage biotech company focused on developing next-generation immunomodulators. Lawyers Marc Recht, Brandon Fenn and Barry Kuang led the Cooley team advising Enavate Sciences.

Related contacts

Marc Recht
Partner, Boston
Brandon W. Fenn
Partner, New York
Barry Kuang
Associate, Boston

Related Practices & Industries

Questa Capital Leads OSSIO’s $27.6 Million Financing

December 2, 2024

Cooley advised Questa Capital, a venture growth equity firm focused on later-stage companies across healthcare, as lead investor in the $27.6 million financing round of OSSIO. OSSIO is a medical device company focused on evolving orthopedic surgery with bio-integrative fixation technology. Partner Brandon Fenn led the Cooley team advising Questa Capital.

Related contacts

Brandon W. Fenn
Partner, New York
Xander Lee
Partner, Santa Monica
Noah Pittard
Partner, Colorado
Alex Abelson
Associate, New York

Related Practices & Industries

View more

Admissions and credentials

New York